1.
|
Phase: Phase IV Type: Prevention Status: Completed Age: 20 to 65 Sponsor: NCI, Other Protocol IDs: AAAC8618, R01CA133595, NCT01050556
|
|
2.
|
Phase: Phase II, Phase I Type: Supportive care, Treatment Status: Completed Age: 18 and over Sponsor: Protocol IDs: MSKCC-91173, NCI-V92-0026
|
|
3.
|
Phase: Phase II, Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CAM201, NCT00291785
|
|
4.
|
Phase: Phase II, Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: PDX-009, NCT00481871
|
|
5.
|
Phase: Phase II Type: Prevention Status: Closed Age: 21 and over Sponsor: NCI Protocol IDs: E-8292, NCI-P95-0066, NCT00002650
|
|
6.
|
Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: TULA-T064031, USO-01103, NCT00033722
|
|
7.
|
Phase: Phase II Type: Treatment Status: Closed Age: 6 months to 65 years Sponsor: Protocol IDs: EUC-47491, NCI-V92-0171
|
|
8.
|
Phase: Phase II Type: Prevention Status: Completed Age: 18 to 80 Sponsor: Other Protocol IDs: ONCO-021-98S, NCT00018551
|
|
9.
|
Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Other Protocol IDs: HOG GU03-67, NCT00216099
|
|
10.
|
Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 9732, H3E-MC-S077, NCT00330915
|
|
11.
|
Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: PDX-008, 2006-002811-29, NCT00364923
|
|
12.
|
Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 11652, H3E-CR-S111, NCT00609518
|
|
13.
|
Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: PDX-015, NCT00998946
|
|
14.
|
Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: PDX-014, 2008-006425-14, NCT01118624
|
|
15.
|
Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: 10-112, NCT01183065
|
|
16.
|
Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 to 75 Sponsor: Other Protocol IDs: HANSOH20090601, NCT01194453
|
|
17.
|
Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: MCV-MCC-9408-2B, NCI-T94-0121O, T94-0121
|
|
18.
|
Phase: Phase I Type: Treatment Status: Completed Age: 21 and over Sponsor: NCI Protocol IDs: LAC-USC-0C941, NCI-T94-0142H, T94-0142
|
|
19.
|
Phase: Phase I Type: Supportive care, Treatment Status: Closed Age: 18 and over Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: UCLA-0005068, TULA-T3004, NCI-G01-2017, NCT00024310
|
|
20.
|
Phase: Phase I Type: Biomarker/Laboratory analysis, Prevention Status: Completed Age: 40 to 72 Sponsor: NCI, Other Protocol IDs: CDR0000393455, P30CA016056, RUH-PHO-0514-0404, RPCI-EPR-20703, AECM-0401022E, NEMCH-6060, NCT00096330
|
|
21.
|
Phase: Phase I Type: Biomarker/Laboratory analysis, Prevention Status: Completed Age: 40 to 72 Sponsor: NCI Protocol IDs: RUH-PHO-0514-0306, PHO-0514-0306, NCT00611000
|
|
22.
|
Phase: No phase specified Type: Prevention Status: Closed Age: 21 to 80 Sponsor: NCI Protocol IDs: DMS-CPHS-10293, NCI-P95-0063
|
|
23.
|
Phase: No phase specified Type: Prevention Status: Closed Age: 75 and under Sponsor: Other Protocol IDs: QMC-UKCAP, EU-20045, NCT00033319
|
|
24.
|
Phase: No phase specified Type: Prevention Status: Closed Age: adult Sponsor: NCI Protocol IDs: SWOG-8745, NCI-P89-0007
|
|
25.
|
Phase: No phase specified Type: Biomarker/Laboratory analysis, Prevention Status: Closed Age: Under 75 Sponsor: NCI Protocol IDs: BWH-1999-P-001674/10, 1999-P-001674/10, BWH-94-06819, NCT00512850
|